As in previous months, September was busy again for Cardium Therapeutics (NYSE MKT: CXM) with the company showcasing its portfolio of products and technologies at leading biotechnology investor conferences.   Of particular interest during the month included a presentation by  Cardium’s Chief Executive Officer and Chairman Christopher Reinhard presented at the BioX Noble Financial Life Sciences Exposition held at the University of Connecticut, Stamford Campus on September 24 – 25, 2012.  The presentation gives a succinct look at the full breadth of Cardium’s portfolio of investments.  Operating for nearly three decades as a full-service investment banking boutique, Noble Financial Capital Markets has become renowned for its research on emerging growth companies.  A video of the presentation can be viewed at:  http://www.slideshare.net/CardiumTherapeutics/cardium-therapeutics-at-noble-biox-life-sciences-exposition-conference

As can be noted in the presentation, Cardium’s Generx® product candidate is a DNA-based angiogenic growth factor therapeutic being developed for the potential treatment of patients with advanced coronary artery disease.  Cardium announced the initiation of the Generx late stage / registration ASPIRE study in March.  Genetic Engineering & Biotechnology News published an article early in the month titled, “Honing In On Gene Delivery Targets” which featured Generx.  The article discussed the ultimate use of transfection—modifying the human organism—and the important discoveries and advancements in the arena provided by Cardium and Generx® related to ischemia.  The full article can be read at http://www.genengnews.com/gen-articles/honing-in-on-gene-delivery-targets/4425/.

News was also released on Excellagen®, Cardium’s FDA-cleared highly-refined fibrillar collagen-based topical gel for the management of full spectrum wounds of different origins ranging from diabetic ulcers to surgical wounds.  In order to effectively advance the commercialization Excellagen, Cardium has formed a new Medical Advisory Board bringing together respected professionals in the wound care sector to assist the company in the commercialization efforts.   More on this development can be read at: http://biotechstocktrader.com/cardium-cxm-forms-medical-advisory-board-to-support-fda-cleared-wound-care-product-639/.

Cardium’s MedPodium® health sciences brand consists of several nutraceutical products that are on the market today, MedPodium® is a portfolio of premium, science-based, easy to use nutraceuticals, metabolics and aesthetics designed to promote health and well-being for today’s active and professional lifestyles.  Leading industry website NutraIngredients-USA.com published an article detailing the rapid growth of nutraceuticals, despite a challenging economic climate.  Specifically, the article cited a recent report from Packaged Facts that said sales of nutritional supplements grew another 7 percent so far in 2012 and should hit $11.5 billion for the year.  Further, the company forecasts that sales will reach $15.5 billion annually by 2017, driven by consumer desire to less-expensive alternatives to traditional medical care.  To learn more about the burgeoning industry, read http://www.nutraingredients-usa.com/Industry/Supplement-sales-hit-11.5-billion-in-U.S.-report-says.

Breaking News – October 1^st, 2012 Cardium Announces the Acquisition of To Go Brands

Cardium Therapeutics (NYSE MKT: CXM) announced that its MedPodium® operating unit has acquired the assets, business and product portfolio of privately-held To Go Brands® to support the expansion of its  health sciences nutraceutical brand platform. To Go Brands has introduced products in a number of food, drug and mass channel retailers, and the company recorded revenues of approximately $1.7 million for the first 6 months of 2012. Continue reading http://phx.corporate-ir.net/phoenix.zhtml?c=77949&p=irol-newsArticle&ID=1739947&highlight=